Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms

被引:160
作者
Balkan, B [1 ]
Li, X [1 ]
机构
[1] Novartis Inst Biomed Res, Summit, NJ 07901 USA
关键词
glucagon-like peptide-1; incretin; autonomic nervous system;
D O I
10.1152/ajpregu.2000.279.4.R1449
中图分类号
Q4 [生理学];
学科分类号
071003 [生理学];
摘要
The incretin glucagonlike peptide-1 (GLP-1)-(7-36) amide is an important factor in prandial glucose homeostasis. Findings that GLP-1 is rapidly inactivated led to the hypothesis that the target of GLP-1 is close to the site of release. To investigate whether the target tissue is located in the hepatoportal system, we administered GLP-1 with glucose into the portal vein of rats and compared this with peripheral GLP-1 administration (jugular vein) and studied the effects of blockers of the nervous system. Portal GLP-1 augmented the insulin response to a portal glucose bolus by 81% (P < 0.01) and markedly improved the glucose disposal rate (P < 0.05). Peripheral administration of GLP-1 produced a similar augmentation of the insulin response (88%)and of the glucose disposal rate. However, only the effect of portal GLP-1 on insulin secretion was blocked by the ganglionic blocker chlorisondamine. The data suggest that prandial beta-cell stimulation by GLP-1 is evoked via a neural reflex triggered in the hepatoportal system. Because absorbed nutrients and GLP-1 first appear in the portal system, this mechanism may constitute a major pathway of GLP-1 action during meals.
引用
收藏
页码:R1449 / R1454
页数:6
相关论文
共 19 条
[1]
AHREN B, 1999, ADV MOL CEL, V29, P175
[2]
AHREN B, 1999, FRONTIERS INSULIN SE, P313
[3]
[4]
DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[5]
Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig [J].
Deacon, CF ;
Pridal, L ;
Klarskov, L ;
Olesen, M ;
Holst, JJ .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 271 (03) :E458-E464
[6]
DUNNING BE, 2000, DIABETES MELLITUS FU, P836
[7]
GLP-1 AND GLP-17-36 AMIDE - INFLUENCES ON BASAL AND STIMULATED INSULIN AND GLUCAGON-SECRETION IN THE MOUSE [J].
FRIDOLF, T ;
BOTTCHER, G ;
SUNDLER, F ;
AHREN, B .
PANCREAS, 1991, 6 (02) :208-215
[8]
GLUCOSE-DEPENDENCY OF THE INSULIN STIMULATORY EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36) AMIDE ON THE RAT PANCREAS [J].
GOKE, R ;
WAGNER, B ;
FEHMANN, HC ;
GOKE, B .
RESEARCH IN EXPERIMENTAL MEDICINE, 1993, 193 (02) :97-103
[9]
Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine [J].
Hansen, L ;
Deacon, CF ;
Orskov, C ;
Holst, JJ .
ENDOCRINOLOGY, 1999, 140 (11) :5356-5363
[10]
Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes [J].
Holst, JJ ;
Deacon, CF .
DIABETES, 1998, 47 (11) :1663-1670